994 related articles for article (PubMed ID: 25881245)
21. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
22. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
23. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.
Scattoni V; Picchio M; Suardi N; Messa C; Freschi M; Roscigno M; Da Pozzo L; Bocciardi A; Rigatti P; Fazio F
Eur Urol; 2007 Aug; 52(2):423-9. PubMed ID: 17397992
[TBL] [Abstract][Full Text] [Related]
24. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
25. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.
Meijer HJ; van Lin EN; Debats OA; Witjes JA; Span PN; Kaanders JH; Barentsz JO
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1405-10. PubMed ID: 21640507
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
27. Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Linxweiler J; Sprenk J; Cascetta K; Pryalukhin A; Hölters S; Zeuschner P; Nini A; Al-Kailani Z; Ezziddin S; Bohle RM; Fries P; Ohlmann CH; Heinzelbecker J; Siemer S; Stöckle M; Junker K; Saar M
J Urol; 2021 Jul; 206(1):88-96. PubMed ID: 33617326
[TBL] [Abstract][Full Text] [Related]
28. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
29. Management of positive lymph nodes following radical prostatectomy.
Heidenreich A; Rieke M; Mahjoub S; Pfister D
Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
[TBL] [Abstract][Full Text] [Related]
30. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
[TBL] [Abstract][Full Text] [Related]
31. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
32. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
33. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
34. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.
Rinnab L; Mottaghy FM; Simon J; Volkmer BG; de Petriconi R; Hautmann RE; Wittbrodt M; Egghart G; Moeller P; Blumstein N; Reske S; Kuefer R
Urol Int; 2008; 81(2):191-7. PubMed ID: 18758218
[TBL] [Abstract][Full Text] [Related]
35. Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan.
Otta-Oshiro RJ; Lista-Mateos F; García-Mediero J; Arranz-Arija JA; García-Prado J; Núñez-Mora C
Actas Urol Esp (Engl Ed); 2019; 43(6):331-335. PubMed ID: 30975547
[TBL] [Abstract][Full Text] [Related]
36. First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches.
Schiavina R; Concetti S; Brunocilla E; Nanni C; Borghesi M; Gentile G; Cevenini M; Bianchi L; Molinaroli E; Fanti S; Martorana G
Urol Int; 2014; 92(2):242-5. PubMed ID: 24334968
[TBL] [Abstract][Full Text] [Related]
37. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
38. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
[TBL] [Abstract][Full Text] [Related]
39. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
[TBL] [Abstract][Full Text] [Related]
40. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
